Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Executes Stock Sales Under 10b5-1 Plan

Christopher Gibson, CEO of Recursion Pharmaceuticals, executed sales of Class A Common Stock on August 7th and 8th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Christopher Gibson, the CEO of Recursion Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On August 7, 2024, Gibson converted 30,000 shares of Class B Common Stock into Class A Common Stock and then sold those 30,000 shares at a price of $7.10 per share.
• On August 8, 2024, Gibson converted 20,000 shares of Class B Common Stock into Class A Common Stock and then sold those 20,000 shares at a price of $6.50 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 27, 2023.
• Following these transactions, Gibson directly owns 758,738 shares of Class A Common Stock.
• Gibson also indirectly owns shares through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).
• Gibson holds options to purchase a total of 1,997,436 shares of Class A Common Stock at various exercise prices and vesting schedules.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports transactions. The existence of a 10b5-1 plan suggests pre-planned sales, mitigating negative interpretations.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders of a publicly traded company buy or sell the company's securities. These filings provide transparency into the transactions of company executives and directors.

Stakeholder Impact

• The stock sales by the CEO could potentially influence investor sentiment, although the existence of a 10b5-1 plan may mitigate concerns.

Key Dates